Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis[1]. Enbrel is a current standard-of-care anti-TNF medication approved to treat moderate-to-severe plaque psoriasis.

The International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) have announced their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.

Amgen (NASDAQ:AMGN) has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125 per share in cash. As announced on Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.

H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) jointly announced that the U.S. Food and Drug Administration (FDA) has approved Brintellix™ (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year[1].

Olivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.

New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.(1)

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). PsA is a chronic, inflammatory condition that causes pain, swelling and stiffness in and around the joints and tendons, and usually occurs in combination with psoriasis.(1,2)